Literature DB >> 2106109

Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue.

W R Meyer1, A R Mayer, M P Diamond, M L Carcangiu, P E Schwartz, A H DeCherney.   

Abstract

We present a case of a 46-year-old woman evaluated for abnormal uterine bleeding and an enlarged uterus, with normal endometrial sampling. Three months of leuprolide acetate injections resulted in a nonenlarging uterus and resolution of iron deficiency anemia and menorrhagia. Intraoperative examination suggested leiomyosarcoma, which was confirmed by postoperative permanent histologic sections. Residual uterine sarcomatous disease was confirmed on reexploration. Similar cases will continue to raise arguments against conservative hormonal intervention in the perimenopausal woman with an enlarged uterus. As the gynecologist gains familiarity with the use of gonadotropin-releasing hormone analogue therapy in the treatment of myomatous uteri, the criteria for hysterectomy will become less rigid and the potential for delay in the diagnosis and treatment of sarcomatous disease will become more common. Physicians must be cognizant of this potential complication of conservative therapy of leiomyomata uteri.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106109

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice.

Authors:  A Zalatnai; J Bocsi; T Csákány; T Fekete; J Lásztity
Journal:  Int J Pancreatol       Date:  1999-08

Review 2.  Menorrhagia. Current drug treatment concepts.

Authors:  M A van Eijkeren; G C Christiaens; P C Scholten; J J Sixma
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 3.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.